☆ 4.3 Article

Real-world long-term effectiveness of ustekinumab in ulcerative colitis: results from a spanish open-label cohort

SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2023)

Related references

Note: Only part of the references are listed.

Review Gastroenterology & Hepatology

Efficacy, Effectiveness, and Safety of Ustekinumab for the Treatment of Ulcerative Colitis: A Systematic Review

Javier P. Gisbert et al.

Summary: This systematic review concludes that ustekinumab has shown efficacy, effectiveness, and safety for the treatment of ulcerative colitis, as demonstrated in randomized controlled trials (and their extension studies) as well as real clinical practice observational studies.

INFLAMMATORY BOWEL DISEASES (2023)

Add to Collection

Article Gastroenterology & Hepatology

OP15 Efficacy of ustekinumab for Ulcerative Colitis through 4 years: Final clinical and endoscopy outcomes from the UNIFI long-term extension

S Danese et al.

Journal of Crohns & Colitis (2023)

Add to Collection

Review Gastroenterology & Hepatology

Rescue Therapies for Steroid-refractory Acute Severe Ulcerative Colitis: A Review

Javier P. Gisbert et al.

Summary: For patients with steroid-refractory ASUC, both standard treatment (cyclosporine and infliximab) and newly developed agents (such as vedolizumab and ustekinumab) are effective options.

JOURNAL OF CROHNS & COLITIS (2023)

Add to Collection

Article Gastroenterology & Hepatology

Meta-analysis: Real-world effectiveness and safety of ustekinumab in patients with ulcerative colitis

Carlos Taxonera et al.

Summary: This study provides evidence on the real-world outcomes of ustekinumab for ulcerative colitis (UC) patients. The meta-analysis confirms the effectiveness of ustekinumab in achieving clinical remission and response in a highly treatment-refractory population of UC patients. The safety profile of ustekinumab is also demonstrated with low rates of adverse events and serious infections.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

Add to Collection

Article Gastroenterology & Hepatology

Re-induction With Intravenous Ustekinumab in Patients With Crohn's Disease and a Loss of Response to This Therapy

Fernando Bermejo et al.

Summary: Intravenous re-induction with ustekinumab is an effective and safe strategy that recovers the response in approximately half of the patients with refractory Crohn's disease who experience a loss of response. Re-induction can be attempted before switching out of the therapy class.

INFLAMMATORY BOWEL DISEASES (2022)

Add to Collection

Editorial Material Gastroenterology & Hepatology

Predictors and Outcomes of Ustekinumab Dose Intensification in Ulcerative Colitis: A Multicenter Cohort Study

Rahul S. Dalal et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Treatment patterns and intensification within 5 year of follow-up of the first-line anti-TNFα used for the treatment of IBD: Results from the VERNE study

G. Batista et al.

Summary: According to the study, around one-third of IBD biologic-naive patients treated with an anti-TNF alpha required treatment intensification, with ulcerative colitis (UC) patients needing earlier intensification. Approximately 40% of patients discontinued the anti-TNF alpha due to inappropriate disease control.

DIGESTIVE AND LIVER DISEASE (2022)

Add to Collection

Article Gastroenterology & Hepatology

Early Symptomatic Improvement After Ustekinumab Therapy in Patients With Ulcerative Colitis: 16-Week Data From the UNIFI Trial

Silvio Danese et al.

Summary: Ustekinumab demonstrates rapid symptomatic relief in patients with ulcerative colitis, as shown by improvements in symptom remission, stool number, stool frequency, rectal bleeding, and inflammatory markers.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Real-world Endoscopic and Histological Outcomes Are Correlated with Ustekinumab Exposure in Patients with Ulcerative Colitis

Dahham Alsoud et al.

Summary: UST treatment can achieve histological remission in refractory UC patients. There is a strong correlation between serum UST concentrations and tissue drug exposure, indicating limited value in measuring tissue exposure.

JOURNAL OF CROHNS & COLITIS (2022)

Add to Collection

Article Gastroenterology & Hepatology

Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension

Maria T. Abreu et al.

Summary: The study confirms the efficacy of ustekinumab in treating patients with ulcerative colitis for up to 3 years, and no new safety issues were observed.

JOURNAL OF CROHNS & COLITIS (2022)

Add to Collection

Article Gastroenterology & Hepatology

Ustekinumab for the treatment o moderate to severe ulcerative colitis: a multicentre UK cohort study

Sailish Honap et al.

Summary: In a real-world setting, ustekinumab showed effectiveness and a reassuring safety profile in patients with UC.

FRONTLINE GASTROENTEROLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Comparative real-world effectiveness of vedolizumab and ustekinumab for patients with ulcerative colitis: a GETAID multicentre cohort study

Antoine Meyer et al.

Summary: The study compared the efficacy of vedolizumab and ustekinumab in treating UC patients who had failed anti-TNF therapy, and found no significant difference between the two in outcomes such as clinical remission. Further research is needed to determine predictive factors for the efficacy of both biological agents.

SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Ustekinumab treatment in ulcerative colitis: Real-world data from the Swedish inflammatory bowel disease quality register

Joel Thunberg et al.

Summary: This study analyzed the clinical outcomes of ustekinumab in patients with ulcerative colitis. The results showed that ustekinumab treatment had a high drug persistence rate and improvements in clinical, biochemical, and health-related quality of life measures among patients with ulcerative colitis.

UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2022)

Add to Collection

Review Gastroenterology & Hepatology

Targeting IL12/23 in ulcerative colitis: update on the role of ustekinumab

Daniela Pugliese et al.

Summary: This article reviews the basis of targeting IL12-23 in UC therapy and summarizes the data from both clinical trials and real-life studies, highlighting the main evidence already available and the research gaps that need to be filled for the optimal usage of ustekinumab in UC.

THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Effectiveness and Durability of Ustekinumab Therapy With or Without Immunomodulators for Ulcerative Colitis Patients in Japan

Yasuhiro Aoki et al.

Summary: The response rate of Japanese ulcerative colitis patients to ustekinumab treatment is similar to that of patients in the US and Europe. There is no significant difference between the ustekinumab monotherapy group and the ustekinumab and immunomodulator combination group in real-world settings.

CROHNS & COLITIS 360 (2022)

Add to Collection

Article Gastroenterology & Hepatology

Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies

William J. Sandborn et al.

Summary: The study indicates that ustekinumab exhibits similar safety and efficacy profiles in patients with ulcerative colitis as it does in those with Crohn's disease, with no significant differences compared to placebo.

INFLAMMATORY BOWEL DISEASES (2021)

Add to Collection

Article

Proactive versus Reactive Therapeutic Drug Monitoring: Why, When, and How?

Manar Shmais et al.

Inflammatory Intestinal Diseases (2021)

Add to Collection

Article Gastroenterology & Hepatology

STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD

Dan Turner et al.

Summary: STRIDE-II presents treatment targets for both adult and pediatric IBD, including long-term and short-term goals. These targets cover aspects such as clinical response, endoscopic healing, quality of life, and growth, providing guidance for improving patient outcomes.

GASTROENTEROLOGY (2021)

Add to Collection

Review Medicine, General & Internal

How to Optimize Treatment With Ustekinumab in Inflammatory Bowel Disease: Lessons Learned From Clinical Trials and Real-World Data

Ana Gutierrez et al.

Summary: Ustekinumab, a fully human monoclonal antibody, has been approved for the treatment of Crohn's disease and ulcerative colitis, demonstrating efficacy and safety in clinical trials. However, treatment options for inflammatory bowel disease remain limited despite its success in patients with refractory disease.

FRONTIERS IN MEDICINE (2021)

Add to Collection

Article Gastroenterology & Hepatology

Effectiveness and Safety of Ustekinumab in Ulcerative Colitis: Real-world Evidence from the ENEIDA Registry

Maria Chaparro et al.

Summary: Ustekinumab has shown durability and effectiveness in the treatment of ulcerative colitis, even in real life situations. Higher levels of serum C-reactive protein were associated with a lower probability of achieving remission. In the short term, 53% of patients showed a positive response to the treatment.

JOURNAL OF CROHNS & COLITIS (2021)

Add to Collection

Article Gastroenterology & Hepatology

Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study

Mathurin Fumery et al.

Summary: This study evaluated the real-world effectiveness and safety of ustekinumab in patients with ulcerative colitis. The findings showed that after 52 weeks of treatment, over one-half of patients with refractory UC were still being treated with ustekinumab and one-third were in steroid-free clinical remission.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2021)

Add to Collection

Article Gastroenterology & Hepatology

Re-induction with intravenous Ustekinumab after secondary loss of response is a valid optimization strategy in Crohn's disease

Sebastiaan ten Bokkel Huinink et al.

Summary: Re-induction with intravenous ustekinumab after secondary loss of response in Crohn's disease leads to continuation of ustekinumab treatment in most patients for at least 1 year and achieves clinical remission in half of the patients after 1 year.

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2021)

Add to Collection

Article Biotechnology & Applied Microbiology

One-year effectiveness and safety of ustekinumab in ulcerative colitis: a multicenter real-world study from Italy

Michele Francesco Chiappetta et al.

Summary: This study retrospectively evaluated the efficacy and safety of ustekinumab in refractory UC patients. The results showed a satisfactory effectiveness and good safety of ustekinumab, with a significant reduction in pMS and steroid use, and a high probability of therapy persistence at week 52.

EXPERT OPINION ON BIOLOGICAL THERAPY (2021)

Add to Collection

Article Gastroenterology & Hepatology

Real-World Effectiveness and Safety of Ustekinumab for Ulcerative Colitis From 2 Tertiary IBD Centers in the United States

Simon J. Hong et al.

Summary: In this retrospective study conducted at two US tertiary inflammatory bowel disease centers, ustekinumab treatment achieved remission in nearly half of UC patients at 12 months and was associated with an overall favorable safety profile. These results are modestly better than the pivotal trials, confirming ustekinumab as an effective and safe option for patients with moderate to severely active ulcerative colitis.

CROHNS & COLITIS 360 (2021)

Add to Collection

Article Gastroenterology & Hepatology

Real-World Effectiveness and Safety of Ustekinumab for Ulcerative Colitis From 2 Tertiary IBD Centers in the United States

Simon J. Hong et al.

Summary: This retrospective study analyzed the effectiveness and safety of ustekinumab in patients with moderately to severely active ulcerative colitis at two US tertiary inflammatory bowel disease centers. The results showed that nearly half of the patients achieved remission at 12 months, with an overall favorable safety profile.

CROHNS & COLITIS 360 (2021)

Add to Collection

Article Gastroenterology & Hepatology

Prevalence of endoscopic improvement and remission according to patient-reported outcomes in ulcerative colitis

Parambir S. Dulai et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)

Add to Collection

Article Gastroenterology & Hepatology

Limitations of the determination of faecal calprotectin in patients with ulcerative colitis and inflammatory polyps

Fernando Bermejo et al.

GASTROENTEROLOGIA Y HEPATOLOGIA (2020)

Add to Collection

Article Gastroenterology & Hepatology

Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis

Omoniyi J. Adedokun et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)

Add to Collection

Article Gastroenterology & Hepatology

Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study

Aurelien Amiot et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)

Add to Collection

Article Gastroenterology & Hepatology

Effectiveness of ustekinumab dose escalation in Crohn's disease patients with insufficient response to standard-dose subcutaneous maintenance therapy

Uri Kopylov et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)

Add to Collection

Article Gastroenterology & Hepatology

Clinical outcomes with ustekinumab as rescue treatment in therapy-refractory or therapy-intolerant ulcerative colitis

Thomas Ochsenkuehn et al.

UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2020)

Add to Collection

Review Gastroenterology & Hepatology

Patient-Reported Outcomes and Endoscopic Appearance of Ulcerative Colitis: A Systematic Review and Meta-analysis

Neeraj Narula et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)

Add to Collection

Article Medicine, General & Internal

Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis

B. E. Sands et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Gastroenterology & Hepatology

Treatment Persistence for Infliximab Versus Adalimumab in Crohn's Disease: A 14-Year Single-Center Experience

Pablo Olivera et al.

INFLAMMATORY BOWEL DISEASES (2017)

Add to Collection

Article Gastroenterology & Hepatology

Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders

Fernando Magro et al.

JOURNAL OF CROHNS & COLITIS (2017)

Add to Collection

Review Medicine, General & Internal

Ulcerative colitis

Ryan Ungaro et al.

LANCET (2017)

Add to Collection

Article Gastroenterology & Hepatology

Higher Rates of Dose Optimisation for Infliximab Responders in Ulcerative Colitis than in Crohn's disease

Sarah O'Donnell et al.

JOURNAL OF CROHNS & COLITIS (2015)

Add to Collection

Article Medicine, Research & Experimental

In vitro assessment of the effects of vedolizumab binding on peripheral blood lymphocytes

Timothy Wyant et al.

MABS (2013)

Add to Collection

Article Gastroenterology & Hepatology

Patients Enrolled in Randomized Controlled Trials Do Not Represent the Inflammatory Bowel Disease Patient Population

Christina Ha et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2012)

Add to Collection

© Peeref 2019-2024. All rights reserved.